<unk>  is a combination of<unk> , a human immunodeficiency virus (HIV-1) protease inhibitor and cobicistat, a CYP3A inhibitor that is FDA approved for the treatment of HIV-1 infection in adult patients.   Common adverse reactions include diarrhea, nausea, rash, headache, abdominal pain, and vomiting.
Darunavir ethanolate and cobicistat
Atazanavir and cobicistat
Lopinavir ritonavir
Dolutegravir / rilpivirine
Sofosbuvir / velpatasvir
Elbasvir / grazoprevir
Ledipasvir / sofosbuvir
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide